Clinical Trial Update: The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating patisiran (ALN-TTR02) for patients with transthyretin-mediated amyloidosis who have prior exposure to the drug; study completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin-mediated Amyloidosis

Drugs mentioned

• Patisiran (patisiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: TTR-mediated Amyloidosis | Phase 2 | Status: COMPLETED | Results posted: 2018-10-30